[
    [
        {
            "time": "",
            "original_text": "转型or消亡？面对biotech后浪“生猛”，人福、罗欣等一众传统药企如何“求生”逆袭？",
            "features": {
                "keywords": [
                    "转型",
                    "biotech",
                    "传统药企",
                    "求生",
                    "逆袭"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "转型or消亡？面对biotech后浪“生猛”，人福、罗欣等一众传统药企如何“求生”逆袭？",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "全球近千万人接种新冠疫苗，拜恩泰科CEO：短时间内无法满足所有需求",
            "features": {
                "keywords": [
                    "新冠疫苗",
                    "拜恩泰科",
                    "需求",
                    "供应"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "全球近千万人接种新冠疫苗，拜恩泰科CEO：短时间内无法满足所有需求",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "全球股市联动日益紧密 2021年的风口在哪里？",
            "features": {
                "keywords": [
                    "全球股市",
                    "联动",
                    "风口",
                    "2021年"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "宏观经济"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "全球股市联动日益紧密 2021年的风口在哪里？",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 1,
                "Market_Scope": 7,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "复星医药(02196-HK)获中证监准增发新H股上限1.1亿",
            "features": {
                "keywords": [
                    "复星医药",
                    "中证监",
                    "增发",
                    "H股"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药(02196-HK)获中证监准增发新H股上限1.1亿",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        }
    ]
]